Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the midpoint. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination. Preliminary imaging data have shown encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, which the company believes could enhance the development of MS therapies, including its investigational candidate Lucid-MS.
The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026. Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. The imaging study's progress represents a significant step toward better understanding demyelination and evaluating treatment efficacy.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets UNBUZZD(TM), and receives royalty payments from sales of the product.
For more information on Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM. The full press release can be viewed at https://ibn.fm/4IZ0y.
